- Home
- PRAX vs VINP Comparison
PRAX vs VINP Comparison
Compare PRAX & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- VINP
- Stock Information
- Founded
- PRAX 2015
- VINP 2009
- Country
- PRAX United States
- VINP Brazil
- Employees
- PRAX N/A
- VINP N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- VINP Investment Managers
- Sector
- PRAX Health Care
- VINP Finance
- Exchange
- PRAX Nasdaq
- VINP Nasdaq
- Market Cap
- PRAX 599.7M
- VINP 616.8M
- IPO Year
- PRAX 2020
- VINP 2021
- Fundamental
- Price
- PRAX $33.79
- VINP $9.45
- Analyst Decision
- PRAX Strong Buy
- VINP Strong Buy
- Analyst Count
- PRAX 9
- VINP 2
- Target Price
- PRAX $123.33
- VINP $13.50
- AVG Volume (30 Days)
- PRAX 570.3K
- VINP 100.5K
- Earning Date
- PRAX 05-12-2025
- VINP 05-08-2025
- Dividend Yield
- PRAX N/A
- VINP 6.88%
- EPS Growth
- PRAX N/A
- VINP N/A
- EPS
- PRAX N/A
- VINP 0.34
- Revenue
- PRAX $8,553,000.00
- VINP $97,136,413.00
- Revenue This Year
- PRAX N/A
- VINP $29.71
- Revenue Next Year
- PRAX $789.73
- VINP $15.39
- P/E Ratio
- PRAX N/A
- VINP $28.10
- Revenue Growth
- PRAX 249.53
- VINP 32.21
- 52 Week Low
- PRAX $26.70
- VINP $8.66
- 52 Week High
- PRAX $91.83
- VINP $11.62
- Technical
- Relative Strength Index (RSI)
- PRAX 43.73
- VINP 45.24
- Support Level
- PRAX $28.79
- VINP $8.66
- Resistance Level
- PRAX $30.88
- VINP $9.67
- Average True Range (ATR)
- PRAX 3.07
- VINP 0.48
- MACD
- PRAX 0.88
- VINP -0.03
- Stochastic Oscillator
- PRAX 56.05
- VINP 46.20
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.